To do this, clinical trials need to use consistent core outcomes. Therefore, HARMONY researchers are running several Delphi Surveys to compile Core Outcome Sets (COS) for specific blood cancers/Hematologic Malignancies. Overview updated 15 September 2021:
What are COS and why do we need help from patients, clinicians, regulators and industry?
HARMONY
Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Login
